sclc3472_S37.txt
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- ANGIOGENESIS+0.480
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.380
- COAGULATION+0.370
- TGF_BETA_SIGNALING+0.370
- KRAS_SIGNALING_UP+0.360
- HEDGEHOG_SIGNALING+0.330
- INFLAMMATORY_RESPONSE+0.320
Top 10 suppressed
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.490
- MYC_TARGETS_V1-0.470
- MYC_TARGETS_V2-0.410
- OXIDATIVE_PHOSPHORYLATION-0.330
- MITOTIC_SPINDLE-0.290
- SPERMATOGENESIS-0.250
- UNFOLDED_PROTEIN_RESPONSE-0.200
- DNA_REPAIR-0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-7386-01A-11R-2016-07 | — | — | 0.919 |
| 2 | TCGA-AO-A03U-01B-21R-A10J-07 | — | D | 0.919 |
| 3 | SRR35579819 | — | A | 0.914 |
| 4 | SRR5088824 | — | — | 0.911 |
| 5 | SRR8518199 | — | A | 0.910 |
| 6 | TCGA-55-6980-01A-11R-1949-07 | — | cohortA1 | 0.905 |
| 7 | TCGA-38-4627-01A-01R-1206-07 | — | cohortA1 | 0.901 |
| 8 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.901 |
| 9 | TCGA-44-6777-01A-11R-1858-07 | — | cohortA1 | 0.901 |
| 10 | SRR8518124 | — | D | 0.900 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |